الصفحة الرئيسية>>MSC2360844

MSC2360844 (Synonyms: MSC2360844; IOA-244)

رقم الكتالوجGC61094

MSC2360844 هو مثبط PI3Kδ فعال وفعال عن طريق الفم وانتقائي ، مع IC50 من 145 نانومتر

Products are for research use only. Not for human use. We do not sell to patients.

MSC2360844 التركيب الكيميائي

Cas No.: 1305267-37-1

الحجم السعر المخزون الكميّة
5mg
278٫00
متوفر
10mg
464٫00
متوفر
25mg
881٫00
متوفر
50mg
1437٫00
متوفر
100mg
2178٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MSC2360844 is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. MSC2360844 shows highly selective against a panel of 278 additional kinases[1].

MSC2360844 (0-10 μM; 1 hours) completely abolished BCR-induced pAkt in Ramos B cells in a concentration-dependent manner with IC50 values of 280 nM[1]. MSC2360844 inhibits B cell proliferation in a concentration-dependent manner with an IC50 of 48 nM. MSC2360844 blocks BCR- and TCR-mediated responses in lymphocytes and TLR-induced IFNα by pDC in human primary cells[1]. Cell Proliferation Assay[1] Cell Line: B cells

MSC2360844 (6.6-66 mg/kg; daily from week 2 to 10) ameliorates disease manifestations in a murine SLE model[1]. Animal Model: NZB/W F1 female mice[1]

[1]. Haselmayer P, et al. Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Front Immunol. 2014 May 22;5:233.

مراجعات

Review for MSC2360844

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MSC2360844

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.